Fernand Labrie
Publications
Page 5 of 8, showing 50 records out of 361 total, starting on record 201, ending on 250
| Publication | Category | Year |
|---|---|---|
| 161. Lacoste, D., Dubé, D., Bélanger, A., Labrie, F. (1989) Effect of 2-week combination therapy with the LHRH agonist [D-Trp6,des-Gly-NH2]LHRH ethylamide and the antiandrogen Flutamide on prostate structure and steroid levels in the dog. Mol. Cell. Endocrinol., 67: 131-138. | Prostate Cancer | 1989 |
| 160. Lacoste, D., Dubé, D., Trudel, C., Bélanger, A., Labrie, F. (1989) Normal gonadal functions and fertility after 23 months of treatment of prepubertal male and female dogs with the GnRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide. J. Androl., 10: 456-465. | Prostate Cancer | 1989 |
| 159. Lacoste, D., Labrie, F., Dubé, D., Bélanger, A., Tice, T., Gilley, R.M., Pledger, K.L. (1989) Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in the dog. J. Steroid Biochem., 33: 1007-1011. | Prostate Cancer | 1989 |
| 158. Monfette, G., Dupont, A., Labrie, F. (1989) Temporary combination therapy with Flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 41-42. | Prostate Cancer | 1989 |
| 157. Monfette, G., Dupont, A., Pinault, S., Gagnon, J., Boivin, J.C., Têtu, B., Labrie, F. (1989) Advantages of downstaging local prostate cancer by 3-month combination therapy prior to radical prostatectomy, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 255-261. | Prostate Cancer | 1989 |
| 156. Pinault, S., Gagnon, J., Monfette, G., Têtu, B., Dupont, A., Labrie, F. (1989) Transrectal ultrasound evaluation of local disease in prostate cancer patients treated with the combination therapy, in: Labrie, F., Lee, F. et Dupont, A., eds: Early State Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 53-62. | Prostate Cancer | 1989 |
| 155. Têtu, B., Labrie, F., Dupont, A., Monfette, G. (1989) Histopathologic effect of combination therapy on normal prostate and prostatic adenocarcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, Exerpta Medica ICS 841, pp 63-76. | Prostate Cancer | 1989 |
| 154. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. | Prostate Cancer | 1988 |
| 153. Bélanger, A., Giasson, M., Cliche, J., Dupont, A., Labrie, F. (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84. | Prostate Cancer | 1988 |
| 152. Belanger, A., Labrie, F., Dupont, A., Brochu, M., Cusan, L. (1988) Endocrine effects of combined treatment with an LHRH agonist in association with Flutamide in metastatic prostatic carcinoma. Clin. Invest. Med., 11: 321-326. | Prostate Cancer | 1988 |
| 151. Dubé, D., Pelletier, G., Labrie, F. (1988) The luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6-des-Gly-NH2(10)]-LHRH ethylamide has no direct effect on spermatogenesis in the rat. Biol. Reprod., 38: 1165-1170. | Prostate Cancer | 1988 |
| 150. Dupont, A., Labrie, F., Giguere, M., Borsanyi, J.-P., Lacourcière, Y., Bergeron, N., Cusan, L., Bélanger, A., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur. J. Cancer Oncol., 24: 659-666. | Prostate Cancer | 1988 |
| 149. Dupont, A., Labrie, F., Giguère, M., Borsanyi, J.-P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist) in untreated patients with advanced prostate cancer, in: Höffken, K., ed. LHRH agonists in Oncology. Symposium on GnRH Analogues, Essen, pp 60-71. | Prostate Cancer | 1988 |
| 148. Labrie, C., Bélanger, A., Labrie, F. (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123: 1412-1417. | Prostate Cancer | 1988 |
| 147. Labrie, F., Bélanger, A., Veilleux, R., Lacoste, D., Labrie, C., Marchetti, B., Poulin, R., Dupont, A., Cusan, L., Luthy, I. (1988) Rationale for maximal androgen withdrawal in the therapy of prostate cancer, in: Furr, M. et Denis, L., eds: Baillieres Clinics in Oncology on Prostate Cancer, London, Saunders Company, pp 597-619. | Prostate Cancer | 1988 |
| 146. Labrie, F., Dupont, A., Bélanger, A., Simard, J., Labrie, C., Poulin, R., Luthy, I., Veilleux, R., Lacoste, D., Marchetti, B., Cusan, L., Manhès, G., Monfette, G., Emond, J. (1988) Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp6,des-Gly-NH210]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience, in: Chretien, M. et McKerns, K.W., eds: Molecular Biology of Brain and Endocrine Peptidergic Systems, New York, Plenum Press, pp 83-101. | Prostate Cancer | 1988 |
| 145. Labrie, F., Dupont, A., Cusan, L., Bélanger, A., Giguère, M., Labrie, C., Lacourcière, Y., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C and D prostate cancer: Today's therapy of choice - Rationale and 5-year clinical experience. Prog. Clin. Biol. Res., 262: 11-63. | Prostate Cancer | 1988 |
| 144. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Emond, J., Monfette, G., Boucher, H., Lachance, R. (1988) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J. Steroid Biochem., 30: 107-117. | Prostate Cancer | 1988 |
| 143. Labrie, F., Dupont, A., Cusan, L., Giguère, M., Bergeron, N., Lacourcière, Y., Bélanger, A., Monfette, G., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide in advanced (stages C and D) previously untreated prostate cancer, in: Motta, M. et Serio, M., eds: Hormonal therapy of prostatic diseases: basic and clinical aspects: International Symposium, Milano, Italy, April 6-8 1987: abstracts of lectures and free communications, pp 312-333. | Prostate Cancer | 1988 |
| 142. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy of LHRH agonists): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Review Article. Prog. Clin. Biol. Res., 260: 41-62. | Prostate Cancer | 1988 |
| 141. Labrie, F., Dupont, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Monfette, G., Emond, J., Bergeron, N. (1988) Benefits of combination therapy with Flutamide in patients relapsing after castration. Br. J. Urol., 61: 341-346. | Prostate Cancer | 1988 |
| 140. Labrie, F., Dupont, A., Giguère, M., Cusan, L., Bergeron, N., Emond, J., Monfette, G., Lacourcière, Y., Boucher, H., Lachance, R. (1988) Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur. J. Cancer Clin. Oncol., 24: 1869-1878. | Prostate Cancer | 1988 |
| 139. Labrie, F., Veilleux, R., Fournier, A. (1988) Low androgen levels induce the development of androgen hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 1138-1147. | Prostate Cancer | 1988 |
| 138. Labrie, F., Veilleux, R., Fournier, A. (1988) Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture. J. Natl. Cancer Inst., 80: 966-970. | Prostate Cancer | 1988 |
| 137. Lacoste, D., St-Arnaud, R., Bélanger, A., Labrie, F. (1988) A pure antiandrogen does not interfere with the LHRH agonist-induced blockade of testicular androgen secretion in the dog. Mol. Cell. Endocrinol., 56: 141-147. | Prostate Cancer | 1988 |
| 136. Lacoste, D., St-Arnaud, R., Caron, S., Bélanger, A., Labrie, F. (1988) The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole. J. Steroid Biochem., 31: 963-970. | Prostate Cancer | 1988 |
| 135. Luthy, I., Bégin, D., Labrie, F. (1988) Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17?-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture. Endocrinology, 123: 1418-1424. | Prostate Cancer | 1988 |
| 134. Luthy, I.A., Bégin, D.J., Labrie, F. (1988) Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J. Steroid Biochem., 31: 845-852. | Prostate Cancer | 1988 |
| 133. Marchetti, B., Labrie, F. (1988) Characteristics of Flutamide action on prostatic and testicular functions in the rat. J. Steroid Biochem., 29: 691-698. | Prostate Cancer | 1988 |
| 132. Marchetti, B., Poulin, R., Plante, M., Labrie, F. (1988) Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J. Steroid Biochem., 31: 411-419. | Prostate Cancer | 1988 |
| 131. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Gagné, C., Brun, D., Giguère, M., Bélanger, A., Cusan, L. (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen and combination treatment with LHRH agonist and Flutamide. J. Clin. Endocrinol. Metab., 66: 314-322. | Prostate Cancer | 1988 |
| 130. Pelletier, G., Labrie, C., Simard, J., Duval, M., Martinoli, M.G., Zhao, H., Labrie, F. (1988) Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in situ hybridization. J. Mol. Endocrinol., 1: 213-223. | Prostate Cancer | 1988 |
| 129. Plante, M., Lapointe, S., Labrie, F. (1988) Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J. Steroid Biochem., 31: 61-64. | Prostate Cancer | 1988 |
| 128. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen Flutamide with medical (LHRH agonist) or surgical castration. Arch. Sex. Behav., 17: 87-98. | Prostate Cancer | 1988 |
| 127. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality and antihormonal therapy in prostate cancer, in: Eicher, W. et Kockott, G., eds: Sexology, Berlin, Springer-Verlag, pp 290-303. | Prostate Cancer | 1988 |
| 126. Simard, J., Labrie, C., Hubert, J.-F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-Gly-NH210]LHRH ethylamide of a subunit and LH? mRNA levels in the rat anterior pituitary gland. Mol. Endocrinol., 2: 775-784. | Prostate Cancer | 1988 |
| 125. St-Arnaud, R., Poyet, P., Walker, P., Labrie, F. (1988) Androgens modulate epidermal growth factor receptor levels in the rat ventral prostate. Mol. Cell. Endocrinol., 56: 21-27. | Prostate Cancer | 1988 |
| 124. Brochu, M., Bélanger, A., Dupont, A., Cusan, L., Labrie, F. (1987) Effects of Flutamide and aminoglutethimide on plasma 5?-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. J. Steroid Biochem., 28: 619-622. | Prostate Cancer | 1987 |
| 123. Dubé, D., Assaf, A., Pelletier, G., Labrie, F. (1987) Morphological study of the effects of an GnRH agonist on the canine testis after 4 months of treatment and recovery. Acta Endocrinol. (Copenh.), 116: 413-417. | Prostate Cancer | 1987 |
| 122. Dubé, D., Pelletier, G., Labrie, F. (1987) Morphological studies of the canine pituitary LH cells after long-term treatment with the LHRH agonist [D-Trp6]LHRH ethylamide. Endocrinology, 120: 589-594. | Prostate Cancer | 1987 |
| 121. Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F. (1987) Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28: 379-384. | Prostate Cancer | 1987 |
| 120. Labrie, F. (1987) Tratamiento del cancer de prostata mediante bloqueo hormonal completo, in: Carcinoma de Prostata: Avances en el Tratamiento Hormonal Patrocinado por la Asociacion Espanola de Urologia Barcelona, pp 61-67. | Prostate Cancer | 1987 |
| 119. Labrie, F., Dupont, A., Bélanger, A. (1987) LHRH agonists and antiandrogens in prostate cancer, in: Catalona, W.J. et Ratliff, T.L., eds: Genitourinary Cancer, Boston, Martinus Nijhoff Publishing, pp 157-200. | Prostate Cancer | 1987 |
| 118. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Giguère, M., Lacourcière, Y., Luthy, I., Bégin, D., Labrie, C., Simard, J., Monfette, G., Emond, J. (1987) Combination therapy in stage C and D prostatic cancer: rationale and 5-year clinical experience, in: Poste, G. et Fidler, I.J., eds: Cancer and Metastatic Reviews, Boston, Martinus Nijhoff Publishing, pp 615-636. | Prostate Cancer | 1987 |
| 117. Labrie, F., Dupont, A., Bélanger, A., Emond, J., Monfette, G., Luthy, I., Simard, J., Lachance, R. (1987) Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer. J. Drug Develop., 1: 34-51. | Prostate Cancer | 1987 |
| 116. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Bergeron, N., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration in prostate cancer: four years of experience, in: D'Agata, R. et Chrousos, G.P., eds: Recent Advances in Adrenal Regulation and Function, New York, Raven Press, pp 209-221. | Prostate Cancer | 1987 |
| 115. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G. (1987) Combined blockade with a pure antiandrogen (Flutamide) should be used without interruption in all patients with previously untreated or treated advanved prostate cancer, in: Beaulieu, E.E., Lacobelli, S. et McGuire, W.L., eds: Endocrinology and Malignancy - Basic and Clinical Issues. Proc. First International Congress on Cancer and Hormones, London, The Parthenon Publishing Group, pp 348-360. | Prostate Cancer | 1987 |
| 114. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy): the minimal endocrine therapy in prostate cancer, in: McCann, S.M. et Weiner, R., eds: Integrative Neuroendocrinology: Molecular Cellular and Clinical Aspects, S. Karger, A.G. Basel, pp 220-234. | Prostate Cancer | 1987 |
| 113. Labrie, F., Dupont, A., Bélanger, A., Giguère, M., Borsanyi, J.P., Lacourcière, Y., Emond, J., Monfette, G., Lachance, R. (1987) The importance of combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer, in: Klijn, J.G.M., Paridaens, R. et Foekens, J.A., eds: Hormonal Manipulation of Cancer: Peptides growth factors and new (anti)-steroidal agents. Monograph Series of the Europea, New York, Raven Press, pp 291-300. | Prostate Cancer | 1987 |
| 112. Labrie, F., Dupont, A., Bélanger, A., Lachance, R. (1987) Flutamide eliminates the risk of disease flare in prostate cancer patients treated with an LHRH agonist. J. Urol., 138: 804-806. | Prostate Cancer | 1987 |